What is Brawn Biotech share price return in the past 10 years?

Brawn Biotech Ltd share price has appreciated 12.5% annually (CAGR) over the past ten years.

Brawn Biotech Ltd - Stock Valuation and Financial Performance

Name: Brawn Biotech
Brand: Brawn Biotech

BSE: 530207 | NSE: | Trading | Small Cap

Place order

Brawn Biotech Share Price

₹22.72 0.82 3.74%
as on 20-Dec'24 16:59

DeciZen - make an informed investing decision on Brawn Biotech

Based on:

Data

M-Cap below 100cr DeciZen not available

Brawn Biotech stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

6.8 Cr.

52-wk low:

14.6

52-wk high:

27.8

Is Brawn Biotech Ltd an attractive stock to invest in?

1. Is Brawn Biotech Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Brawn Biotech Ltd is a average quality company.

2. Is Brawn Biotech Ltd undervalued or overvalued?

The key valuation ratios of Brawn Biotech Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Brawn Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Brawn Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Brawn Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	12%	26.4%	29%	27.8%	23%	9.7%	-3.6%	-25.7%	-5.9%	-26.1%	-
Value Creation Index ⓘ	-0.1	0.9	1.1	1.0	0.7	-0.3	-1.3	-2.8	-1.4	-2.9	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	38.7	46.9	60.6	55.8	65.2	49.6	35	8.6	22.2	16.5	16
Sales YoY Gr.	-	21.3%	29.2%	-7.9%	16.9%	-23.9%	-29.5%	-75.4%	157.9%	-25.8%	-
Adj EPS ⓘ	1	3.3	3.3	4.2	4.1	1.8	-2.5	-5.5	-2.9	-4.1	-4.2
YoY Gr.	-	243.8%	0.3%	26.3%	-1%	-57.7%	-241.1%	NA	NA	NA	-
BVPS (₹) ⓘ	16.5	18.4	23.1	25.4	28.9	30.9	29.3	24.1	21	16.9	14.1
Adj Net Profit ⓘ	0.3	1	1	1.3	1.2	0.5	-0.7	-1.7	-0.9	-1.2	-1
Cash Flow from Ops. ⓘ	0.2	0.1	1.4	-1.5	0.2	-0.1	0	0.2	0.3	0	-
Debt/CF from Ops. ⓘ	0.5	2.4	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-9%	-24%	-22.2%	-25.8%
Adj EPS ⓘ	-217.6%	-200%	NA	NA
BVPSⓘ	0.3%	-10.2%	-16.8%	-19.7%
Share Price	12.5%	-4%	5.2%	-1.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	6	18.9	15.9	17.2	15.3	5.9	-8.2	-20.6	-12.8	-21.8	-26.9
Op. Profit Mgn % ⓘ	1.5	3.2	2.1	3.5	1.8	1.5	-1.7	-23.3	-1.4	-8.9	-11.7
Net Profit Mgn % ⓘ	0.8	2.1	1.6	2.3	1.9	1.1	-2.1	-19.1	-3.9	-7.5	-7.6
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	127	105	85	120	122	152	171	545	214	298	175
Cash Conv. Cycle ⓘ	28	28	31	32	27	46	70	274	57	99	66

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years -22.17%

Sales growth is not so good in last 4 quarters at -30.27%

Latest Financials - Brawn Biotech Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-4.2	-
TTM Sales (₹ Cr.)	16.5	-
BVPS (₹.) ⓘ	14.1	-
Reserves (₹ Cr.) ⓘ	1	-
P/BV ⓘ	1.61	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	14.63 / 27.82
All Time Low / High (₹)	0.40 / 95.60
Market Cap (₹ Cr.)	6.8
Equity (₹ Cr.)	3
Face Value (₹)	10
Industry PE ⓘ	62.3

Management X-Ray of Brawn Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Brawn Biotech

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Brawn Biotech

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	38.65	46.88	60.55	55.78	65.18	49.62	34.98	8.62	22.23	16.49
Operating Expenses ⓘ	38.09	45.45	59.31	53.82	64.01	48.88	35.57	10.63	22.53	17.97
Manufacturing Costs	0.07	0.20	0.06	0.06	0.08	1.28	1.41	0.19	0.34	0.20
Material Costs	33.67	40.52	52.19	48.85	58.50	42.10	30.02	6.59	19.18	14.36
Employee Cost	1.52	1.86	1.98	2.98	3.02	3.08	2.36	1.80	1.40	1.40
Other Costs ⓘ	2.82	2.86	5.08	1.93	2.41	2.41	1.78	2.04	1.62	2
Operating Profit ⓘ	0.56	1.44	1.24	1.96	1.17	0.74	-0.60	-2.01	-0.30	-1.47
Operating Profit Margin (%)	1.4%	3.1%	2.0%	3.5%	1.8%	1.5%	-1.7%	-23.3%	-1.4%	-8.9%
Other Income ⓘ	0.05	0.01	0.62	0.09	0.74	0.17	0.31	0	0.01	0.09
Interest ⓘ	0.10	0.11	0.07	0.06	0.07	0.05	0.04	0.06	0.01	0.06
Depreciation ⓘ	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.05	0.11	0.10
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0.48	1.30	1.76	1.96	1.81	0.82	-0.36	-2.12	-0.41	-1.54
Tax ⓘ	0.19	0.36	0.36	0.68	0.47	0.23	0.19	-0.47	0.46	-0.30
Profit After Tax	0.28	0.95	1.39	1.28	1.33	0.59	-0.55	-1.64	-0.87	-1.25
PAT Margin (%)	0.7%	2.0%	2.3%	2.3%	2.0%	1.2%	-1.6%	-19.1%	-3.9%	-7.6%
Adjusted EPS (₹)	1.0	3.2	4.6	4.3	4.4	2.0	-1.8	-5.5	-2.9	-4.2
Dividend Payout Ratio (%)	0%	32%	32%	23%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	4.94	5.53	6.92	7.63	8.66	9.26	8.80	7.22	6.31	5.07
Share Capital ⓘ	3	3	3	3	3	3	3	3	3	3
Reserves ⓘ	1.94	2.53	3.92	4.63	5.66	6.26	5.79	4.22	3.31	2.06
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0.05	0	0	0	0	0	0	0	0
Long Term Debt	0	0.05	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	6.80	4.95	6.82	11.23	10.35	8.59	2.66	4.05	6.47	5.67
Others Liabilities ⓘ	2.27	3.40	3.25	3.63	3.45	2.37	2.27	1.89	1.59	3.39
Total Liabilities ⓘ	14	13.93	16.98	22.49	22.45	20.22	13.72	13.16	14.37	14.13
Fixed Assets
Gross Block	0.24	0.32	0.36	0.36	0.36	0.38	0.38	0.67	0.77	0.78
Accumulated Depreciation	0.05	0.08	0.10	0.14	0.17	0.20	0.24	0.29	0.40	0.45
Net Fixed Assetsⓘ	0.19	0.24	0.25	0.22	0.19	0.18	0.14	0.39	0.37	0.33
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investmentsⓘ	0.03	0.03	0	0	0	0	0	0	0	0
Inventories	1.03	0.50	0.37	0.35	0.34	0.39	0.26	4.72	4.79	6.02
Trade Receivables	9.22	9.20	13.02	15.05	16.46	15	9.28	2.81	5.32	3.88
Cash Equivalents	0.25	0.17	2	0.40	0.54	0.40	0.40	0.22	0.44	0.40
Others Assetsⓘ	3.29	3.79	1.34	6.47	4.92	4.26	3.65	5.02	3.45	3.50
Total Assets ⓘ	14	13.93	16.98	22.49	22.45	20.22	13.72	13.16	14.37	14.13

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	0.23	0.05	1.37	-1.54	0.21	-0.08	0.03	0.19	0.32	-0.03
PBT ⓘ	0.48	1.30	1.76	1.96	1.81	0.82	-0.36	-2.12	-0.41	-1.54
Adjustment ⓘ	0.13	0.13	2.20	0.09	0.15	0.10	0.15	0.19	0.07	0.06
Changes in Working Capital ⓘ	-0.38	-1.02	-1.83	-2.31	-0.93	-0.76	0.51	2.12	0.65	1.46
Tax Paid ⓘ	0	-0.36	-0.76	-1.29	-0.82	-0.23	-0.28	0	0.01	0
Cash Flow From Investing Activity ⓘ	-0.12	-0.08	0.57	0	0	-0.02	0	-0.30	-0.10	-0.01
Capex	0	0	-0.03	0	0	-0.02	0	-0.30	-0.10	-0.01
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.12	-0.08	0.61	0	0	0	0	0	0	0
Cash Flow From Financing Activityⓘ	0	-0.05	-0.11	-0.06	-0.06	-0.05	-0.04	-0.06	-0.01	0
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0.05	-0.05	0	0	0	0	0	0	0
Interest Paid ⓘ	-0.10	-0.10	-0.07	-0.06	-0.06	-0.05	0	-0.06	-0.01	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.10	0	0	0	0	0	-0.04	0	0	0
Net Cash Flow ⓘ	0.11	-0.08	1.83	-1.60	0.15	-0.14	0	-0.17	0.21	-0.04

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	5.91	18.15	22.39	17.62	16.37	6.6	-6.1	-20.53	-12.83	-21.93
ROCE (%)	11.98	26.39	29.04	27.75	23.03	9.74	-3.57	-25.66	-5.94	-26.12
Asset Turnover Ratio	2.79	3.36	3.92	2.83	2.9	2.33	2.06	0.64	1.61	1.16
PAT to CFO Conversion(x)	0.82	0.05	0.99	-1.2	0.16	-0.14	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	83	72	67	92	88	116	127	256	67	102
Inventory Days	13	6	3	2	2	3	3	105	78	120
Payable Days	74	53	41	67	67	82	68	186	100	154

Brawn Biotech Ltd Stock News

Brawn Biotech Ltd FAQs

What is the share price of Brawn Biotech?

Company share prices are keep on changing according to the market conditions. The closing price of Brawn Biotech on 20-Dec-2024 16:59 is ₹22.72.

What is the market cap of Brawn Biotech?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Brawn Biotech stood at ₹6.82.

What is the P/E ratio of Brawn Biotech?

The latest P/E ratio of Brawn Biotech as of 20-Dec-2024 16:59 is 0.00.

What is the P/B ratio of Brawn Biotech?

The latest P/B ratio of Brawn Biotech as of 20-Dec-2024 16:59 is 1.61.

What is the 52-week high and low of Brawn Biotech?

The 52-week high of Brawn Biotech is ₹27.82 and the 52-week low is ₹14.63.

What is the TTM revenue of Brawn Biotech?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Brawn Biotech is ₹16.49 ( Cr.) .

About Brawn Biotech Ltd

Brawn Pharmaceuticals was incorporated in the year 1985 it operates in health care sector in India and outside India. It has started its business by selling pharmaceutical formulations manufactured by other companyâ€™s loan license basis. The company is located in New Delhi, India.

Business Profile:

The company involves in the manufacture, contract manufacture, and supply of pharmaceutical products. It is basically engages in the manufacture of tablets, capsules, and oral syrups.

Products of the company

Company's products are made under various categories namely Analgesics, Antibiotics, Anti Tuberculosis, Anti-inflammatory, Antipyretic, Anti Malarial, B Complex and Amino Acids, Cardiovascular drugs, Antiphyscotropic drugs, Tranquilizers, Antacids.